Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares Therapeutics, currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

Heptares receives upfront option grant and exercise payments and is also eligible to receive future development and commercial milestone payments up to $190 million plus royalties on product sales.